US20020040129A1 - Nucleotide sequences encoding the glk-gene - Google Patents

Nucleotide sequences encoding the glk-gene Download PDF

Info

Publication number
US20020040129A1
US20020040129A1 US09/725,898 US72589800A US2002040129A1 US 20020040129 A1 US20020040129 A1 US 20020040129A1 US 72589800 A US72589800 A US 72589800A US 2002040129 A1 US2002040129 A1 US 2002040129A1
Authority
US
United States
Prior art keywords
polynucleotide
process according
sequence
gene
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/725,898
Other languages
English (en)
Inventor
Bettina Mockel
Walter Pfefferle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa GmbH filed Critical Degussa GmbH
Assigned to DEGUSSA-HULS AG reassignment DEGUSSA-HULS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOCKEL, BETTINA, PFEFFERLE, WALTER
Assigned to DEGUSSA AG reassignment DEGUSSA AG MERGER (SEE DOCUMENT FOR DETAILS). Assignors: DEGUSSA-HULS AKTIENGESELLSCHAFT
Publication of US20020040129A1 publication Critical patent/US20020040129A1/en
Priority to US10/197,541 priority Critical patent/US6913910B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine

Definitions

  • the invention provides nucleotide sequences encoding the glk-gene and processes for the fermentative production of L amino acids, in particular L-lysine, using coryneform bacteria in which the glk-gene is enhanced.
  • L-amino acids in particular L-lysine, are used in human medicine and in the pharmaceutical industry, but especially in animal nutrition.
  • L-amino acids can be produced by fermentation of strains of coryneform bacteria, in particular Corynebacterium glutamicum.
  • Improvements in production processes may involve fermentation technology measures, such as for example stirring and provision of oxygen, or the composition of the nutrient media, such as for example the sugar concentration during fermentation, or the working-up to the product form by for example ion exchange chromatography, or the intrinsic output properties of the microorganism itself.
  • strains are obtained that are resistant to antimetabolites, such as for example the lysine-analogon S-(2-aminoethyl)-cysteine or that are auxotrophic for regulatorily important metabolites and produce L-amino acids such as for example L-lysine.
  • antimetabolites such as for example the lysine-analogon S-(2-aminoethyl)-cysteine or that are auxotrophic for regulatorily important metabolites and produce L-amino acids such as for example L-lysine.
  • L-amino acids in particular L-lysine
  • L-lysine are used in human medicine, in the pharmaceutical industry and in particular in animal nutrition. It is therefore of general interest to provide new improved processes for the production of L-amino acids, in particular L-lysine.
  • L-lysine or lysine are mentioned hereinafter, this should be understood to mean not only the bases per se but also the salts, for example lysine monohydrochloride or lysine sulfate.
  • the invention provides an isolated polynucleotide obtained from coryneform bacteria, containing a polynucleotide sequence selected from the following group
  • the invention also provides a polynucleotide that is preferably a recombinant DNA replicable in coryneform bacteria.
  • the invention likewise provides a polynucleotide that is an RNA.
  • the invention moreover provides a polynucleotide with the aforementioned features which polynucleotide is preferably a replicable DNA, containing: (i)
  • the invention in addition provides:
  • the invention moreover provides polynucleotides that substantially comprise a polynucleotide sequence, that can be obtained by screening by means of hybridisation of a corresponding gene library that contains the complete gene with the polynucleotide sequence corresponding to SEQ ID NO:1 with a probe that contains the sequence of the aforementioned polynucleotide according to SEQ ID NO:1 or a fragment thereof, and isolation of the aforementioned DNA sequence.
  • Polynucleotide sequences according to the invention are suitable as hybridisation probes for RNA, cDNA and DNA in order to isolate in full length cDNA that code for glucokinase and to isolate such cDNA or genes that have a high degree of similarity to the sequence of the glucokinase gene.
  • Polynucleotide sequences according to the invention are furthermore suitable as primers for producing DNA of genes that code for glucokinase, by the polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • Such oligonucleotides serving as probes or primers contain at least 30, preferably at least 20, and most particularly preferably at least 15 successive bases. Oligonucleotides with a length of at least 40 or 50 nucleotides are also suitable.
  • isolated means separated from its natural environment.
  • Polynucleotide refers in general to polyribonucleotides and polydeoxyribonucleotides, in which connection these terms may refer to unmodified RNA or DNA or modified RNA or DNA.
  • polypeptides are understood peptides or proteins that contain two or more amino acids bound via peptide bonds.
  • polypeptides according to the invention include a polypeptide according to SEQ ID NO:2, in particular those having the biological activity of glucokinase as well as those that are at least 70% identical to the polypeptide according to SEQ ID NO:2, preferably at least 80% and particularly at least 90% to 95% identical to the polypeptide according to SEQ ID NO:2 and that have the aforementioned activity.
  • the invention furthermore relates to a process for the fermentative production of L-amino acids, in particular L-lysine, using coryneform bacteria that in particular already produce an L-amino acid, and in which the nucleotide sequences coding for the glk-gene are enhanced, in particular are overexpressed.
  • the term “enhancement” describes in this connection increasing the intracellular activity of one or more enzymes in a microorganism that are coded by the corresponding DNA, by for example increasing the number of copies of the gene and/or genes, using a strong promoter or using a gene that codes for a corresponding enzyme having a high activity, and optionally combining these measures.
  • the microorganisms that are the subject of the present invention can produce amino acids, in particular L-lysine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol.
  • the microorganisms may be types of coryneform bacteria, in particular of the genus Corynebacterium. In the genus Corynebacterium there should in particular be mentioned the type Corynebacterium glutamicum, which is known to those in the specialist field for its ability to produce L-amino acids.
  • Suitable strains of the genus Corynebacterium in particular of the type Corynebacterium glutamicum , are for example the following known wild type strains:
  • the inventors have succeeded in isolating the new glk-gene from C. glutamicum coding for the enzyme glucokinase (EC 2.7.1.2).
  • plasmids such as pBR322 (Bolivar, Life Sciences, 25, 807-818 (1979)) or pUC9 (Vieira et al., 1982, Gene, 19:259-268) may also be used.
  • Particularly suitable as hosts are those E. coli strains that are restriction-defective and recombinant-defective.
  • An example of such strains is the strain DH5 ⁇ mcr that has been described by Grant et al.
  • Coding DNA sequences that are obtained from SEQ ID NO:1 due to the degeneracy of the genetic code are likewise included in the invention.
  • Conservative amino acid exchanges such as, for example, the exchange of glycine by alanine or of aspartic acid by glutamic acid in proteins are known in the art as sense mutations that do not lead to any fundamental change in the activity of the protein, i.e. that are functionally neutral. It is furthermore known that changes at the N- and/or C-terminus of a protein do not substantially affect, or may even stabilise, its function. The person skilled in the art may find information on this in, inter alia, Ben-Bassat et al.
  • DNA sequences that hybridise with SEQ ID NO:1 or portions of SEQ ID NO:1 are included in the invention.
  • DNA sequences that are produced by the polymerase chain reaction (PCR) using primers that are formed from SEQ ID NO:1 are also intended to be included in the invention.
  • PCR polymerase chain reaction
  • Such oligonucleotides typically have a length of at least 15 nucleotides.
  • coryneform bacteria produce L-amino acids, in particular L-lysine, in an improved manner after overexpression of the glk-gene.
  • the number of copies of the corresponding genes can be increased, or the promoter and regulation region or the ribosome binding site that is located upstream of the structure gene can be mutated.
  • Expression cassettes that are incorporated upstream to the structure gene act in the same way. It is in addition possible by means of inducible promoters to increase the expression during the course of the fermentative production of L-amino acid. The expression is similarly improved by measures adopted to increase the lifetime of the m-RNA.
  • the enzyme activity may be increased by preventing the decomposition of the enzyme protein.
  • the genes or gene constructs may be present either in plasmids with different numbers of copies or may be integrated and amplified in the chromosome. Alternatively, overexpression of the relevant genes may be achieved by changing the composition of the medium and cultivation conditions.
  • the glk-gene according to the invention was overexpressed by means of plasmids.
  • Suitable plasmids are those that are replicated in coryneform bacteria.
  • Numerous known plasmid vectors such as, for example, pZ1 (Menkel et al., Applied and Environmental Microbiology (1989) 64: 549-554), pEKEx1 (Eikmanns et al., Gene 102:93-98 (1991)) or pHS2-1 (Sonnen et al., Gene 107:69-74 (1991)) are based on the cryptic plasmids pHM1519, pBL1 or pGA1.
  • Other plasmid vectors such as, for example, those that are based on pCG4 (U.S. Pat. No.
  • plasmid vectors by means of which the process of gene amplification by integration into the chromosome can be employed, as has been described for example by Reinscheid et al. (Applied and Environmental Microbiology 60, 126-132 (1994)) for the duplication and/or amplification of the hom-thrB-operon.
  • the full gene is cloned in a plasmid vector that can replicate in a host (typically E. coli ) but not in C. glutamicum .
  • Suitable vectors that may be mentioned are for example pSUP301 (Simon et al., Bio/Technology 1, 784-791 (1983)), pK18mob or pK19mob (Schäfer et al., Gene 145, 69-73 (1994)), pGEM-T (Promega corporation, Madison, Wis., USA), pCR2.1-TOPO (Shuman (1994), Journal of Biological Chemistry 269:32678-84; U.S. Pat. No.
  • the plasmid vector that contains the gene to be amplified is then transferred by conjugation or transformation into the desired strain of C. glutamicum .
  • the method of conjugation is described, for example, by Schfer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Methods of transformation are described, for example, in Thierbach et al.
  • the invention accordingly also provides a process for the fermentative production of L-amino acids, in particular L-lysine, in which a strain transformed with a plasmid vector is used, and the plasmid vector carries the nucleotide sequence of the gene coding for the enzyme glucokinase.
  • L-amino acids in particular L-lysine
  • L-lysine may be advantageous for the production of L-amino acids, in particular L-lysine, to enhance, as well as the glk-gene, further genes of the biosynthesis pathway of the desired L-amino acid so that one or more enzymes of the relevant biosynthesis pathway, glycolysis, anaplerotic, citric acid cycle or of the amino acid export is overexpressed.
  • L-amino acids in particular L-lysine
  • the microorganisms produced according to the invention may be cultured continuously or batchwise in a batch process (batch cultivation) or in a fed batch or repeated fed batch process in order to produce L-amino acids, in particular L-lysine.
  • a batch process batch cultivation
  • a fed batch or repeated fed batch process in order to produce L-amino acids, in particular L-lysine.
  • the culture medium to be used must suitably satisfy the requirements of the relevant strains. Descriptions of culture media for various microorganisms are given in the handbook “Manual of Methods for General Bacteriology” of the American Society for Bacteriology (Washington D.C., USA, 1981).
  • sugars and carbohydrates such as for example glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats such as for example soya bean oil, sunflower oil, groundnut oil and coconut oil, fatty acids such as for example palmitic acid, stearic acid and linoleic acid, alcohols such as for example glycerol, ethanol, and organic acids such as for example acetic acid, may be used. These substances may be used individually or as a mixture.
  • nitrogen source organic nitrogen-containing compounds such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, may be used.
  • the nitrogen sources may be used individually or as a mixture.
  • phosphorus source phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate, or the corresponding sodium-containing salts, may be used.
  • the culture medium must furthermore contain salts of metals that are necessary for growth such as, for example, magnesium sulfate or iron sulfate.
  • essential growth substances such as amino acids and vitamins may be used in addition to the substances mentioned above.
  • suitable precursors may be added to the culture medium.
  • the aforementioned feedstock substances may be added to the culture in the form of a single batch, or may be metered in in a suitable way during the cultivation.
  • Alkaline compounds such as sodium hydroxide, potassium hydroxide, ammonia or ammonia water or acidic compounds such as phosphoric acid or sulfuric acid may be used in an appropriate manner in order to regulate the pH of the culture.
  • Antifoaming agents such as, for example, fatty acid polyglycol esters may be used to regulate foam formation.
  • Suitable selectively acting substances such as, for example, antibiotics may be added to the medium in order to maintain the stability of plasmids.
  • Oxygen or oxygen-containing gas mixtures such as, for example, air are introduced into the culture in order to maintain aerobic conditions.
  • the temperature of the culture is normally 20° C. to 45° C. and preferably 25° C. to 40° C. The culture is continued until a maximum yield of lysine has been formed. This target is normally achieved within 10 hours to 160 hours.
  • the invention accordingly also provides a process for the fermentative production of L-amino acids, in particular L-lysine, in which the following steps are carried out:
  • L-lysine may be carried out by anion exchange chromatography followed by ninhydrin derivatisation, as described for example by Spackman et al. (Analytical Chemistry, 30, (1958), 1190).
  • the process according to the invention allows the fermentative production of L-amino acids, in particular L-lysine.
  • FIG. 1 Map of the plasmid pEC-K18mob2
  • FIG. 2 Map of the plasmid pEC-K18mob2glkexp
  • oriV ColE1-like origin of pMB1
  • rep Plasmid-coded replication region of C. glutamicum plasmid pGA1
  • Kan Resistance gene for kanamycin
  • glk glk-gene of C.glutamicum
  • EcoRI Cleavage site of the restriction enzyme EcoRI
  • HindIII Cleavage site of the restriction enzyme HindIII
  • Ecl136II Cleavage site of the restriction enzyme Ecl136II
  • the cosmid-DNA treated in this way was mixed with the treated ATCC13032-DNA and the batch was treated with T4-DNA-ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-ligase, Code no.27-0870-04).
  • T4-DNA-ligase Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-ligase, Code no.27-0870-04.
  • the ligation mixture was then packed in phages with the aid of the Gigapack II XL Packing Extracts (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217).
  • Gigapack II XL Packing Extracts Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217.
  • the cosmid-DNA of an individual colony was isolated using the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) according to the manufacturer's instructions and partially cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Product No. 27-0913-02).
  • the DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, Product Description SAP, Product No. 1758250). After gel electrophoresis separation the cosmid fragments were isolated in the large region from 1500 to 2000 bp using the QiaExII Gel Extraction Kit (Product No.
  • the nucleotide sequence obtained is shown in SEQ ID NO:1. Analysis of the nucleotide sequence revealed an open reading frame of 969 base pairs, which was termed the glk-gene. The glk-gene codes for a protein of 323 amino acids.
  • Chromosomal DNA was isolated from the strain ATCC 13032 according to the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994)). On the basis of the sequence of the glk-gene known for C. glutamicum from Example 2 the following oligonucleotides were selected for the polymerase chain reaction:
  • the illustrated primers were synthesised by ARK Scientific GmbH Biosystems (Darmstadt, Germany) and the PCR reaction was carried out according to the standard PCR method of Innis et al. (PCR protocols. A Guide to Methods and Applications, 1990, Academic Press) with Pwo polymerase from Roche Diagnostics GmbH (Mannheim, Germany). With the aid of the polymerase chain reaction the primers permit the amplification of a ca. 1.45 kb size DNA fragment which carries the glk-gene with the potential promoter region. The DNA sequence of the amplified DNA fragment was checked by sequencing.
  • the E. coli - C. glutamicum shuttle vector was constructed according to the prior art.
  • the vector contains the replication region rep of the plasmid pGA1 including the replication effector per (U.S. Pat. No. 5,175,108; Nesvera et al., Journal of Bacteriology 179, 1525-1532 (1997)), the aph(3′)-IIa-gene of the transposon Tn5 imparting resistance to kanamycin (Beck et al., Gene 19, 327-336 (1982)), the replication region oriV of the plasmid pMB1 (Sutcliffe, Cold Spring Harbor Symposium on Quantitative Biology 43, 77-90 (1979)), the lacZ ⁇ gene fragment including the lac promoter and a multiple cloning site (mcs) (Norrander, J.
  • Plasmid DNA was isolated from a transformant using the QIAprep Spin Miniprep Kit from Qiagen and was checked by restriction with the restriction enzyme EcoRI and HindIII followed by agarose gel electrophoresis (0.8%).
  • the plasmid was named pEC-K18mob2 and is shown in FIG. 1.
  • E. coli - C. glutamicum shuttle vector pEC-K18mob2 described in Example 3.2 was used as vector. DNA of this plasmid was completely cleaved with the restriction enzyme Ecl136II and then dephosphorylated with shrimp alkaline phosphatase (Roche Diagnostics GmbH, Mannheim, Germany, Product Description SAP, Product No. 1758250).
  • the glk fragment obtained as described in Example 3.1 was mixed with the prepared vector pEC-K18mob2 and the batch was treated with T4-DNA-ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-Ligase, Code no.27-0870-04).
  • the ligation batch was transformed into the E. coli strain DH5 ⁇ (mcr (Grant, 1990, Proceedings of the National Academy of Sciences U.S.A., 87:4645-4649).
  • the selection of plasmid-carrying cells was made by plating out the transformation batch onto LB-agar (Lennox, 1955, Virology, 1:190) with 25 mg/l of kanamycin.
  • Plasmid DNA was isolated from a transformant using the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) according to the manufacturer's instructions and cleaved with the restriction enzymes EcoRI and XbaI in order to check the plasmid by subsequent agarose gel electrophoresis.
  • the plasmid obtained was named pEC-K18mob2glkexp and is shown in FIG. 2.
  • strain C. glutamicum RES167 (Schäfer, A. et al., Journal Bacteriological 176: 7309-731(1994)) was transformed with the plasmid pEC-K18mob2glkexp using the electroporation method described by Liebl et al., (FEMS Microbiology Letters, 53:299-303 (1989)).
  • the selection of the tranformants was made on LBHIS agar consisting of 18.5 g/l brain-heart infusion broth, 0.5 M sorbitol, 5 g/l Bacto-Trypton, 2,5 g/l Bacto-Yeast Extract, 5 g/l NaCl and 18 g/l Bacto-Agar, that had been supplemented with 25 mg/l kanamycin. Incubation was carried out at 33° C. for two days.
  • Plasmid DNA was isolated from a transformant by the usual methods (Peters-Wendisch et al., Microbiology, 144:915-927 (1998)), cleaved with the restriction endonucleases EcoRI and XbaI, and the plasmid was checked by subsequent agarose gel electrophoresis.
  • the strain obtained was named C. glutamicum RES167/pEC-K18mob2glkexp.
  • the strain C. glutamicum RES167/pEC-K18mob2glkexp obtained in Example 4 was cultivated in a nutrient medium suitable for producing lysine, and the lysine content in the culture supernatant was determined.
  • the strain was first incubated at 33° C. for 24 hours on agar plates with the appropriate antibiotic (brain-heart agar with kanamycin (25 mg/l)).
  • a preculture was inoculated using this agar plate culture (10 ml medium in 100 ml Erlenmeyer flask).
  • the full medium CgIII was used as medium for the preculture.
  • Medium Cg III NaCl 2.5 g/l Bacto-Pepton 10 g/l Bacto-Yeast Extract 10 g/l Glucose (separately autoclaved) 2% (w/v)
  • the pH was adjusted to pH 7.4
  • Kanamycin 25 mg/l was added to this medium.
  • the pre-culture was incubated on a shaker for 16 hours at 33° C. and 240 rpm.
  • a main culture was inoculated from this pre-culture so that the initial optical density (660 nm) of the main culture was 0.05.
  • the medium MM was used for the main culture.
  • CSL, MOPS and the salt solution were adjusted with ammonia water to pH 7 and autoclaved.
  • the sterile substrate and vitamin solutions as well as the dry autoclaved CaCO 3 were then added.
  • Cultivation takes place in a 10 ml volume in a 100 ml Erlenmeyer flask with baffles. Kanamycin (25 mg/l) was added. Cultivation was performed at 33° C. and 80% atmospheric humidity.
  • the OD was measured at a measurement wavelength of 660 nm using the Biomek 1000 (Beckmann Instruments GmbH, Kunststoff).
  • the amount of lysine formed was measured with an amino acid analyser from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivatisation with ninhydrin detection.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
US09/725,898 1999-12-02 2000-11-30 Nucleotide sequences encoding the glk-gene Abandoned US20020040129A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/197,541 US6913910B2 (en) 1999-12-02 2002-07-18 Nucleotide sequences coding for the glk-gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19958159A DE19958159A1 (de) 1999-12-02 1999-12-02 Neue für das glk-Gen codierende Nukleotidsequenzen
DE19958159.2 1999-12-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/197,541 Division US6913910B2 (en) 1999-12-02 2002-07-18 Nucleotide sequences coding for the glk-gene

Publications (1)

Publication Number Publication Date
US20020040129A1 true US20020040129A1 (en) 2002-04-04

Family

ID=7931209

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/725,898 Abandoned US20020040129A1 (en) 1999-12-02 2000-11-30 Nucleotide sequences encoding the glk-gene
US10/197,541 Expired - Lifetime US6913910B2 (en) 1999-12-02 2002-07-18 Nucleotide sequences coding for the glk-gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/197,541 Expired - Lifetime US6913910B2 (en) 1999-12-02 2002-07-18 Nucleotide sequences coding for the glk-gene

Country Status (16)

Country Link
US (2) US20020040129A1 (cs)
EP (1) EP1106694A1 (cs)
JP (1) JP2001204481A (cs)
KR (1) KR20010062078A (cs)
CN (1) CN1305000A (cs)
AU (1) AU7198800A (cs)
BR (1) BR0005678A (cs)
CA (1) CA2325227A1 (cs)
DE (1) DE19958159A1 (cs)
HU (1) HUP0004783A2 (cs)
ID (1) ID28565A (cs)
MX (1) MXPA00011815A (cs)
PL (1) PL344237A1 (cs)
RU (1) RU2000129933A (cs)
SK (1) SK17942000A3 (cs)
ZA (1) ZA200007078B (cs)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032895A1 (en) * 2001-11-19 2005-02-10 Yunik Chang Medicament for the treatment of viral skin and tumour diseases
US20060088919A1 (en) * 2004-10-22 2006-04-27 Rybak Konstantin V Method for producing L-amino acids using bacteria of the Enterobacteriaceae family
US7306932B2 (en) 2001-12-20 2007-12-11 Degussa Ag Coryneform bacteria with altered glucokinase activity in the production of L-lysine

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10032173A1 (de) 2000-07-01 2002-01-17 Degussa Neue für das plsC-Gen kodierende Nukleotidsequenzen
KR20250139930A (ko) * 2024-03-14 2025-09-24 대상 주식회사 L-라이신 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 l-라이신의 생산 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0655149B2 (ja) * 1985-03-12 1994-07-27 協和醗酵工業株式会社 Ｌ―リジンの製造法
CA2135644C (en) * 1992-05-14 2009-01-27 Elisabetta Vegeto Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
DE19644567A1 (de) * 1996-10-26 1998-04-30 Forschungszentrum Juelich Gmbh Mikrobielle Herstellung von Substanzen aus dem aromatischen Stoffwechsel / II
DE19644566A1 (de) * 1996-10-26 1998-04-30 Forschungszentrum Juelich Gmbh Mikrobielle Herstellung von Substanzen aus dem aromatischen Stoffwechsel / I
DE19818541C2 (de) * 1998-04-24 2003-04-10 Forschungszentrum Juelich Gmbh Mikrobielle Herstellung von Substanzen aus dem aromatischen Stoffwechsel / III
DE19924365A1 (de) * 1999-05-27 2000-11-30 Degussa Verfahren zur fermentativen Herstellung von L-Aminosäuren und für das accDA Gen codierende Nukleotidsequenzen
KR100856512B1 (ko) * 1999-06-25 2008-09-04 백광산업 주식회사 탄소 대사 및 에너지 생산과 관련된 단백질을 코딩하는코리네박테리움 글루타미쿰 유전자
JP4623825B2 (ja) 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032895A1 (en) * 2001-11-19 2005-02-10 Yunik Chang Medicament for the treatment of viral skin and tumour diseases
US7306932B2 (en) 2001-12-20 2007-12-11 Degussa Ag Coryneform bacteria with altered glucokinase activity in the production of L-lysine
US20060088919A1 (en) * 2004-10-22 2006-04-27 Rybak Konstantin V Method for producing L-amino acids using bacteria of the Enterobacteriaceae family
US7915018B2 (en) * 2004-10-22 2011-03-29 Ajinomoto Co., Inc. Method for producing L-amino acids using bacteria of the Enterobacteriaceae family
US20110143403A1 (en) * 2004-10-22 2011-06-16 Konstantin Vyacheslavovich Rybak Method for producing l-amino acids using bacteria of the enterobacteriaceae family
US8728774B2 (en) 2004-10-22 2014-05-20 Ajinomoto Co., Inc. Method for producing L-amino acids using bacteria of the enterobacteriaceae family
US8785161B2 (en) 2004-10-22 2014-07-22 Ajinomoto Co., Inc. Method for producing L-amino acids using bacteria of the enterobacteriaceae family

Also Published As

Publication number Publication date
PL344237A1 (en) 2001-06-04
US20030022320A1 (en) 2003-01-30
US6913910B2 (en) 2005-07-05
MXPA00011815A (es) 2002-06-04
SK17942000A3 (sk) 2001-10-08
JP2001204481A (ja) 2001-07-31
EP1106694A1 (de) 2001-06-13
BR0005678A (pt) 2001-08-21
HU0004783D0 (cs) 2001-02-28
CA2325227A1 (en) 2001-06-02
ID28565A (id) 2001-06-07
AU7198800A (en) 2001-06-07
ZA200007078B (en) 2001-06-06
KR20010062078A (ko) 2001-07-07
DE19958159A1 (de) 2001-06-07
HUP0004783A2 (hu) 2003-03-28
CN1305000A (zh) 2001-07-25
RU2000129933A (ru) 2003-01-10

Similar Documents

Publication Publication Date Title
US20020127663A1 (en) Nucleotide sequences which code for the zwa1 gene
US20010049123A1 (en) Nucleotide sequences encoding the dapC gene and process for the production of L-lysine
US6759218B2 (en) Nucleotide sequences coding for the glbO gene
US6913910B2 (en) Nucleotide sequences coding for the glk-gene
US6818432B2 (en) Nucleotide sequences encoding the ptsH gene
US20020094554A1 (en) Nucleotide sequences encoding the ptsH gene
AU7254800A (en) New nucleotide sequences coding for the ptsH gene
US6806068B1 (en) Nucleotide sequences which encode the pfk gene
US6830921B2 (en) Nucleotide sequences which code for the ACP gene
US6680186B2 (en) Nucleotide sequences which encode plsC gene
KR20010051876A (ko) ｐｆｋＡ 유전자를 암호화하는 신규한 뉴클레오타이드 서열
US20020042107A1 (en) Nucleotide sequences which code for the fadD15 gene
US7306939B2 (en) Nucleotide sequences encoding the gpm gene
US6987015B1 (en) Nucleotide sequences encoding the pfkA gene
EP1278860B1 (en) Nucleotide sequences which code for the cma gene
US20040092710A1 (en) Nucleotide sequences coding for the cdsA gene
US6638753B2 (en) Nucleotide sequences which code for the cma gene
US20020155555A1 (en) Nucleotide sequences which code for the pgsA2 gene
US20020034794A1 (en) Nucleotide sequences which encode the gpsA gene
KR20020097245A (ko) ｃｄｓＡ 유전자를 암호화하는 뉴클레오타이드 서열
US20020102667A1 (en) Novel nucleotide sequences coding for the cls gene
US20020137912A1 (en) Nucleotide sequences which code for the cstA gene
KR20020097244A (ko) ｐｇｓＡ2 유전자를 암호화하는 신규한 뉴클레오타이드 서열

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEGUSSA-HULS AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOCKEL, BETTINA;PFEFFERLE, WALTER;REEL/FRAME:011822/0148;SIGNING DATES FROM 20010111 TO 20010113

AS Assignment

Owner name: DEGUSSA AG, GERMANY

Free format text: MERGER;ASSIGNOR:DEGUSSA-HULS AKTIENGESELLSCHAFT;REEL/FRAME:012322/0909

Effective date: 20010209

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION